Better Therapeutics to Participate in Two Upcoming Investor Events

Better Therapeutics (NASDAQ: BTTX) announced CEO Kevin Appelbaum will participate in two investor events.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/20/2022 - 04:00 PM EST

SAN FRANCISCO--(BUSINESS WIRE)--

Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:

A virtual fireside chat hosted by LifeSci Capital on January 26 from 12 – 1 p.m. EST. The management team will discuss the current treatment paradigm for cardiometabolic diseases, Better Therapeutics’ approach for treating behavioral root causes using prescription digital therapeutics (PDT), and its lead candidate BT-001, a PDT for treating uncontrolled type 2 diabetes in adults, currently undergoing a potentially pivotal trial. To register for the call, please email Robert Fromberg (rfromberg@lifescicapital.com).
The Cowen 42^nd Annual Health Care Conference taking place March 7 – 9 in Boston, MA, including a fireside chat on Monday, March 7^th, from 2:10-2:40 pm EST.
A replay of both firesides will be available on the Presentations and Events section on the Better Therapeutics investor site (www.investors.bettertx.com) for approximately 90 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com

BTTX-PR